NATCO Pharma Limited (NATCOPHARM.NS)
INR 775.5
(3.88%)
INR 775.5
(3.88%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 10.05 Billion INR | -23.1% |
| 2022 | 13.08 Billion INR | 21.0% |
| 2021 | 10.81 Billion INR | 85.93% |
| 2020 | 5.81 Billion INR | -34.42% |
| 2019 | 8.86 Billion INR | 0.53% |
| 2018 | 8.81 Billion INR | 14.19% |
| 2017 | 7.72 Billion INR | 11.86% |
| 2016 | 6.9 Billion INR | 39.35% |
| 2015 | 4.95 Billion INR | 35.88% |
| 2014 | 3.64 Billion INR | 19.79% |
| 2013 | 3.04 Billion INR | 25.5% |
| 2012 | 2.42 Billion INR | 28.64% |
| 2011 | 1.88 Billion INR | -29.95% |
| 2010 | 2.69 Billion INR | 2.1% |
| 2009 | 2.63 Billion INR | -0.66% |
| 2008 | 2.65 Billion INR | 54.73% |
| 2007 | 1.71 Billion INR | 62.43% |
| 2006 | 1.05 Billion INR | 805.71% |
| 2005 | 116.57 Million INR | 63.52% |
| 2004 | 71.29 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 FY | 10.05 Billion INR | -23.1% |
| 2023 Q4 | 2.35 Billion INR | -17.59% |
| 2023 Q1 | 4.01 Billion INR | -12.78% |
| 2023 Q2 | 3.72 Billion INR | -7.15% |
| 2023 Q3 | 2.85 Billion INR | -23.25% |
| 2022 Q3 | 3.41 Billion INR | 9.18% |
| 2022 Q1 | 2.72 Billion INR | -28.46% |
| 2022 Q4 | 4.6 Billion INR | 34.74% |
| 2022 FY | 13.08 Billion INR | 21.0% |
| 2022 Q2 | 3.12 Billion INR | 14.67% |
| 2021 Q3 | 1.75 Billion INR | -56.39% |
| 2021 FY | 10.81 Billion INR | 85.93% |
| 2021 Q1 | 2.48 Billion INR | -2.47% |
| 2021 Q2 | 4.01 Billion INR | 61.39% |
| 2021 Q4 | 3.81 Billion INR | 117.58% |
| 2020 Q1 | 3.59 Billion INR | 48.96% |
| 2020 Q4 | 2.55 Billion INR | 206.78% |
| 2020 Q3 | -2.39 Billion INR | -208.93% |
| 2020 Q2 | 2.19 Billion INR | -38.99% |
| 2020 FY | 5.81 Billion INR | -34.42% |
| 2019 Q4 | 2.41 Billion INR | 146.08% |
| 2019 FY | 8.86 Billion INR | 0.53% |
| 2019 Q1 | 2.54 Billion INR | 2.87% |
| 2019 Q2 | 2.87 Billion INR | 13.11% |
| 2019 Q3 | 981 Million INR | -65.87% |
| 2018 Q2 | 2.64 Billion INR | 6.32% |
| 2018 Q1 | 2.48 Billion INR | -1.51% |
| 2018 Q4 | 2.47 Billion INR | 110.21% |
| 2018 FY | 8.81 Billion INR | 14.19% |
| 2018 Q3 | 1.17 Billion INR | -55.49% |
| 2017 Q2 | 2.27 Billion INR | 9.24% |
| 2017 Q4 | 2.52 Billion INR | -9.8% |
| 2017 Q3 | 2.79 Billion INR | 23.07% |
| 2017 Q1 | 2.07 Billion INR | 5.53% |
| 2017 FY | 7.72 Billion INR | 11.86% |
| 2016 FY | 6.9 Billion INR | 39.35% |
| 2016 Q1 | 1.9 Billion INR | 16.5% |
| 2016 Q2 | 2.2 Billion INR | 16.17% |
| 2016 Q4 | 1.97 Billion INR | -15.45% |
| 2016 Q3 | 2.33 Billion INR | 5.44% |
| 2015 Q3 | 2.13 Billion INR | 63.65% |
| 2015 Q1 | 1.19 Billion INR | 11.6% |
| 2015 Q4 | 1.63 Billion INR | -23.6% |
| 2015 FY | 4.95 Billion INR | 35.88% |
| 2015 Q2 | 1.3 Billion INR | 9.13% |
| 2014 Q2 | 896.9 Million INR | -13.72% |
| 2014 Q4 | 1.07 Billion INR | 44.57% |
| 2014 Q3 | 741.66 Million INR | -17.31% |
| 2014 Q1 | 1.03 Billion INR | 7.43% |
| 2014 FY | 3.64 Billion INR | 19.79% |
| 2013 Q2 | 979.6 Million INR | 17.5% |
| 2013 Q4 | 967.6 Million INR | 109.82% |
| 2013 FY | 3.04 Billion INR | 25.5% |
| 2013 Q1 | 833.7 Million INR | 8.36% |
| 2013 Q3 | 461.16 Million INR | -52.92% |
| 2012 FY | 2.42 Billion INR | 28.64% |
| 2012 Q3 | 427.52 Million INR | -35.19% |
| 2012 Q2 | 659.7 Million INR | -11.37% |
| 2012 Q1 | 744.3 Million INR | 21.34% |
| 2012 Q4 | 769.4 Million INR | 79.96% |
| 2011 FY | 1.88 Billion INR | -29.95% |
| 2011 Q2 | 597.4 Million INR | 16.66% |
| 2011 Q3 | 302.3 Million INR | -49.4% |
| 2011 Q4 | 613.4 Million INR | 102.91% |
| 2011 Q1 | 512.1 Million INR | 0.0% |
| 2010 FY | 2.69 Billion INR | 2.1% |
| 2009 FY | 2.63 Billion INR | -0.66% |
| 2008 FY | 2.65 Billion INR | 54.73% |
| 2007 FY | 1.71 Billion INR | 62.43% |
| 2006 FY | 1.05 Billion INR | 805.71% |
| 2005 FY | 116.57 Million INR | 63.52% |
| 2004 FY | 71.29 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 36.621% |
| Hester Biosciences Limited | 908.84 Million INR | -1006.685% |
| Aarti Drugs Limited | 1.16 Billion INR | -761.514% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | -227.153% |
| Albert David Limited | 1.02 Billion INR | -880.171% |
| Alembic Limited | 872.45 Million INR | -1052.835% |
| Alkem Laboratories Limited | 32.83 Billion INR | 69.368% |
| Bafna Pharmaceuticals Limited | 455.58 Million INR | -2107.711% |
| Bajaj HealthCare Limited | 985.34 Million INR | -920.759% |
| Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -147378.006% |
| Brooks Laboratories Limited | 51.18 Million INR | -19552.208% |
| Eris Lifesciences Limited | 4.94 Billion INR | -103.482% |
| FDC Limited | 3.49 Billion INR | -187.391% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 13.596% |
| Gufic Biosciences Limited | 1.18 Billion INR | -747.64% |
| Hikal Limited | 4.46 Billion INR | -125.324% |
| Ind-Swift Limited | 946.56 Million INR | -962.577% |
| Innova Captab Limited | 931.03 Million INR | -980.309% |
| IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | -356.974% |
| Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | -2193.467% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 30.414% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -836.337% |
| Lupin Limited | 125.09 Billion INR | 91.96% |
| Mangalam Drugs & Organics Limited | 162.22 Million INR | -6099.916% |
| Medico Remedies Limited | 59.67 Million INR | -16754.629% |
| Morepen Laboratories Limited | 1.98 Billion INR | -406.076% |
| Nectar Lifesciences Limited | 932.7 Million INR | -978.375% |
| Orchid Pharma Limited | 800.77 Million INR | -1156.039% |
| Procter & Gamble Health Limited | 2.99 Billion INR | -235.782% |
| RPG Life Sciences Limited | 1.63 Billion INR | -514.98% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -2338.735% |
| Sigachi Industries Limited | 579.88 Million INR | -1634.476% |
| Solara Active Pharma Sciences Limited | 2.55 Billion INR | -293.798% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -617.0% |
| Themis Medicare Limited | 1.12 Billion INR | -793.411% |
| Unichem Laboratories Limited | 6.72 Billion INR | -49.542% |
| Vaishali Pharma Limited | 84.02 Million INR | -11869.677% |
| Wanbury Limited | 978.96 Million INR | -927.411% |
| Windlas Biotech Limited | 1 Billion INR | -899.295% |
| ZIM Laboratories Limited | 1.01 Billion INR | -892.836% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -373.499% |
| Ipca Laboratories Limited | 18.98 Billion INR | 47.029% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 93.477% |
| Venus Remedies Limited | 1.91 Billion INR | -424.87% |
| Sakar Healthcare Limited | 204.07 Million INR | -4828.484% |
| Aurobindo Pharma Limited | 55.65 Billion INR | 81.929% |
| Divi's Laboratories Limited | 14.17 Billion INR | 29.019% |
| AstraZeneca Pharma India Limited | 2.47 Billion INR | -306.63% |
| Mankind Pharma Limited | 29.27 Billion INR | 65.641% |
| Sequent Scientific Limited | 2.9 Billion INR | -246.611% |
| Laurus Labs Limited | 11.9 Billion INR | 15.549% |
| Neuland Laboratories Limited | 2.92 Billion INR | -243.306% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 32.006% |
| Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 78.578% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 91.967% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | -380.316% |
| Wockhardt Limited | 8.48 Billion INR | -18.608% |
| Bal Pharma Limited | 555.62 Million INR | -1710.21% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 89.51% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -608.698% |
| Par Drugs and Chemicals Limited | 58.28 Million INR | -17155.69% |
| Caplin Point Laboratories Limited | 2.17 Billion INR | -362.543% |
| Shilpa Medicare Limited | 3.33 Billion INR | -201.664% |
| Valiant Laboratories Limited | 138.02 Million INR | -7186.874% |
| Ajanta Pharma Limited | 30.46 Billion INR | 66.983% |
| Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -70666.2% |
| Granules India Limited | 10.31 Billion INR | 2.471% |
| Medicamen Biotech Limited | 335.16 Million INR | -2900.892% |
| Syncom Formulations (India) Limited | 345.63 Million INR | -2810.023% |
| Piramal Enterprises Limited | 63.65 Billion INR | 84.199% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 53.048% |
| Suven Life Sciences Limited | 109.75 Million INR | -9064.465% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -21691.316% |
| Strides Pharma Science Limited | 9.16 Billion INR | -9.776% |
| Indoco Remedies Limited | 12.06 Billion INR | 16.609% |
| Alpa Laboratories Limited | 127.38 Million INR | -7796.059% |
| Lasa Supergenerics Limited | 291.17 Million INR | -3354.292% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | -226.898% |